Industries de la santé
16 Avril 2014
In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. |Results published...
Plus d'articles...
- Keeping Austria on the Pharma Map – Local Experts Discuss the Need for Cooperation and Interaction at EuroMeeting 2014
- Quality control of mitochondria as a defense against disease
- Monitoring Inactive Hepatitis B Patients is Cost-Effective Strategy for Shanghai
- Reconnaissance scientifique internationale de l’efficacité thérapeutique du dispositif médical Cefaly®, une innovation technologique mise au point par la firme liégeoise Cefaly Technology dans le traitement de la migraine